The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Gynecological Cancer Année : 2023

The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia

Vesna Kesic
Mario Preti
Pedro Vieira-Baptista
Federica Bevilacqua
  • Fonction : Auteur
Jacob Bornstein
  • Fonction : Auteur
Maggie Cruickshank
  • Fonction : Auteur
Emre Erzeneoglu
  • Fonction : Auteur
Niccolò Gallio
  • Fonction : Auteur
Murat Gultekin
Debra Heller
  • Fonction : Auteur
Maria Kyrgiou
  • Fonction : Auteur
Tatjana Madić
  • Fonction : Auteur
François Planchamp
Sigrid Regauer
  • Fonction : Auteur
Olaf Reich
  • Fonction : Auteur
Bilal Esat Temiz
  • Fonction : Auteur
Linn Woelber
  • Fonction : Auteur
Jana Zodzika
  • Fonction : Auteur
Colleen Stockdale
  • Fonction : Auteur

Résumé

The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) developed consensus statements on pre-invasive vulvar lesions in order to improve the quality of care for patients with vaginal intraepithelial neoplasia (VaIN). The management of VaIN varies according to the grade of the lesion: VaIN 1 (low grade vaginal squamous intraepithelial lesions (SIL)) can be subjected to follow-up, while VaIN 2–3 (high-grade vaginal SIL) should be treated. Treatment needs individualization according to the patient’s characteristics, disease extension and previous therapeutic procedures. Surgical excision is the mainstay of treatment and should be performed if invasion cannot be excluded. Total vaginectomy is used only in highly selected cases of extensive and persistent disease. Carbon dioxide (CO 2 ) laser may be used as both an ablation method and an excisional one. Reported cure rates after laser excision and laser ablation are similar. Topical agents are useful for persistent, multifocal lesions or for patients who cannot undergo surgical treatment. Imiquimod was associated with the lowest recurrence rate, highest human papillomavirus (HPV) clearance, and can be considered the best topical approach. Trichloroacetic acid and 5-fluorouracil are historical options and should be discouraged. For VaIN after hysterectomy for cervical intraepithelial neoplasia (CIN) 3, laser vaporization and topical agents are not the best options, since they cannot reach epithelium buried in the vaginal scar. In these cases surgical options are preferable. Brachytherapy has a high overall success rate but due to late side effects should be reserved for poor surgical candidates, having multifocal disease, and with failed prior treatments. VaIN tends to recur and ensuring patient adherence to close follow-up visits is of the utmost importance. The first evaluation should be performed at 6 months with cytology and an HPV test during 2 years and annually thereafter. The implementation of vaccination against HPV infection is expected to contribute to the prevention of VaIN and thus cancer of the vagina. The effects of treatment can have an impact on quality of life and result in psychological and psychosexual issues which should be addressed. Patients with VaIN need clear and up-to-date information on a range of treatment options including risks and benefits, as well as the need for follow-up and the risk of recurrence.
Fichier principal
Vignette du fichier
ijgc-2022-004213.pdf (1.23 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-04337751 , version 1 (12-12-2023)

Identifiants

Citer

Vesna Kesic, Xavier Carcopino, Mario Preti, Pedro Vieira-Baptista, Federica Bevilacqua, et al.. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia. International Journal of Gynecological Cancer, 2023, 33 (4), pp.446 - 461. ⟨10.1136/ijgc-2022-004213⟩. ⟨hal-04337751⟩
31 Consultations
17 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More